mutated SOD1 gene-silencing siRNA therapy (Thera Neuropharma)

N/A

Report date: 2025/03/20 15:58:17
NME

Base Information

Drug Namemutated SOD1 gene-silencing siRNA therapy (Thera Neuropharma)
Drug Alias NameRNAi therapy (RXi)mutated SOD1 gene-silencing siRNA therapy (RXi)mutated SOD1 gene-silencing siRNA therapy (CytRx)RNAi therapy (CytRx)mutated SOD1 gene-silencing siRNA therapy (Galena Biopharma) +[6] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > microRNASmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionSuperoxide dismutase modulators
TargetsSuperoxide dismutase
Therapy Area/IndicationsAmyotrophic Lateral Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLadRx Corp
China Registration ClassN/A

Develop Information

Active CompaniesThera Neuropharma
Inactive CompaniesLadRx CorpSellas Life Sciences Group IncPhio Pharmaceuticals Corp
Active IndicationsAmyotrophic Lateral Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A